Belite Bio, Inc.(BLTE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BLTE Belite Bio, Inc.

Not Yet Opened 11-04 16:00:00 EST

154.01

+1.84

+1.21%

盘后154.01

+0.000.00%

19:42 EST

High156.97	Low150.65	Vol82.73K
Open156.97	D1 Closing152.17	Amplitude4.15%
Mkt Cap6.20B	Tradable Cap3.01B	Total Shares40.27M
T/O12.65M	T/O Rate0.42%	Tradable Shares19.55M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BLTE","market":"US","secType":"STK","nameCN":"Belite Bio, Inc.","latestPrice":154.01,"timestamp":1793826000000,"preClose":152.17,"halted":0,"volume":82730,"hourTrading":{"tag":"盘后","latestPrice":154.01,"preClose":154.01,"latestTime":"19:42 EST","volume":912,"amount":140448.77,"timestamp":1793839325062,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.01209173950187293,"floatShares":19550700,"shares":40272144,"eps":-2.738223,"marketStatus":"Not Yet Opened","change":1.84,"latestTime":"11-04 16:00:00 EST","open":156.97,"high":156.97,"low":150.65,"amount":12651681.3201,"amplitude":0.041532,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.738223,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1793869200000},"marketStatusCode":0,"adr":0,"adrRate":1,"listingDate":1651204800000,"exchange":"NASDAQ","adjPreClose":152.17,"preHourTrading":{"tag":"盘前","latestPrice":156.97,"preClose":152.17,"latestTime":"09:29 EST","volume":122,"amount":18638.08762,"timestamp":1793802599986,"change":4.8,"changeRate":0.031544,"amplitude":0.041927},"postHourTrading":{"tag":"盘后","latestPrice":154.01,"preClose":154.01,"latestTime":"19:42 EST","volume":912,"amount":140448.77,"timestamp":1793839325062,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.61296,"impliedVol":0.7127,"impliedVolPercentile":0.7},"requestUrl":"/m/hq/s/BLTE","defaultTab":"news","newsList":[{"id":"2679242250","title":"US Research Roundup-Baker Hughes, Brinker International, GE Vernova","url":"https://stock-news.laohu8.com/highlight/detail?id=2679242250","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679242250?lang=en_us&edition=fundamental","pubTime":"2026-10-29 15:25","pubTimestamp":1793258720,"startTime":"0","endTime":"0","summary":"US RESEARCH ROUNDUP-Baker Hughes, Brinker International, GE VernovaOct 29 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several US-listed companies, including Ba","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261029:nL3N46F0MU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLTE","RSPU","BANC","APH","SNPE","AUR","BNTC","AEP","AXSM","ALK","CVNA","CCS","PEX","AVBH","GOOG","BBWI","AVTR","BOED","BRO","AXGN","BOEG","BSX","CNC","CBC","BKR","ARHS","BIIB","BCAX","ALGN","CPF","FCOM","GOOP","ALKT","ARCC","ADP","SKYY","ANT","BXP","GLAM","ETSY","BOOT","AMLX","CNP","BLKB","EAT","GOOGL","CSTL","CHRW","BA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677963494","title":"Two new option listings and one option delisting on October 22nd","url":"https://stock-news.laohu8.com/highlight/detail?id=2677963494","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677963494?lang=en_us&edition=fundamental","pubTime":"2026-10-22 20:36","pubTimestamp":1792672566,"startTime":"0","endTime":"0","summary":"New option listings for October 22nd include Belite Bio Inc (ADR) (BLTE) and Getty Images Holdings, Inc. (GETYQ). Option delistings effective Octob...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/two-new-option-listings-and-one-option-delisting-on-october-22nd-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/two-new-option-listings-and-one-option-delisting-on-october-22nd-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DINT","CVY","ARMH","AADR","SAPH","DIVL","BLTE","BK4007","APIE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124625844","title":"Morgan Stanley Initiates Eight Biotech Names, Rating Seven Overweight","url":"https://stock-news.laohu8.com/highlight/detail?id=1124625844","media":"Analyst Calls","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124625844?lang=en_us&edition=fundamental","pubTime":"2026-10-20 10:11","pubTimestamp":1792462284,"startTime":"0","endTime":"0","summary":"","market":"sg","thumbnail":"https://static.tigerbbs.com/96e20408c3934de428b82e38a778cc26","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/96e20408c3934de428b82e38a778cc26"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Morgan Stanley Initiates Eight Biotech Names, Rating Seven Overweight","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGNX","CMPS","TRVI","PTCT","AVLN","BLTE"],"isVideo":true,"video":{"duration":320,"video_url":"https://news-video-sg.skytigris.cn/videos/remotion/3928/render_3928_1792461663591.mp4","video_thumbnail":"https://news-video-sg.skytigris.cn/videos/covers/3928.webp","audio_url":"https://news-video-sg.skytigris.cn/videos/remotion/3928/tts/voiceover_2510d0822d39909bff1e8933.mp3","isAI":true},"gpt_icon":0},{"id":"2676946502","title":"Belite Bio, Inc: Announces Uplisting to the NASDAQ Global Select Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2676946502","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676946502?lang=en_us&edition=fundamental","pubTime":"2026-10-19 18:04","pubTimestamp":1792404245,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261019:nFWN4630O5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BLTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676502606","title":"Belite Bio Moves to NASDAQ Global Select Market on Oct. 19","url":"https://stock-news.laohu8.com/highlight/detail?id=2676502606","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676502606?lang=en_us&edition=fundamental","pubTime":"2026-10-19 18:01","pubTimestamp":1792404064,"startTime":"0","endTime":"0","summary":"Belite Bio Moves to Nasdaq Global Select Market on Oct. 19Belite Bio will transfer its securities listing from the Nasdaq Capital Market to the Nasdaq Global Select Market.Trading on Nasdaq's highest ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261019:nNDL5JL5bk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","LU0314104364.USD","BK4588","BK4585","SG9999014013.SGD","NDAQ","BK4112","IE00BN0W2V16.EUR","SG9999014039.USD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","BK4007","BLTE","SG9999014005.SGD","IE00BN0W2W23.USD","BCDF","IE00BQXX3C00.GBP","LU2210149790.SGD","IE00BQXX3D17.EUR","IE00BQXX3F31.USD","IE00BGHQF748.EUR","SG9999014021.USD","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675553263","title":"Belite Bio Price Target Maintained with a $245.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2675553263","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675553263?lang=en_us&edition=fundamental","pubTime":"2026-10-16 06:37","pubTimestamp":1792103820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BLTE/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLTE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675058162","title":"Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE), Vertex Pharmaceuticals (VRTX) and Corcept Therapeutics (CORT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2675058162","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675058162?lang=en_us&edition=fundamental","pubTime":"2026-10-15 19:40","pubTimestamp":1792064416,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Belite Bio, Inc. ADR (BLTE), Vertex Pharmaceuticals ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-belite-bio-inc-adr-blte-vertex-pharmaceuticals-vrtx-and-corcept-therapeutics-cort-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-belite-bio-inc-adr-blte-vertex-pharmaceuticals-vrtx-and-corcept-therapeutics-cort-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BIB","SAPH","IE0002270589.USD","VRTX","LU1674673691.USD","IDNA","BK4567","DINT","IBB","BBH","VERX","IE00BJJMRZ35.SGD","CORT","HCSG","LU1035775433.USD","BK4588","PBE","GNMX","LU2236285917.USD","LU0432979614.USD","ARMH","BLTE","LU0823416689.USD","BK4533","CVY","LU0289739699.SGD","DIVL","SG9999001176.USD","SG9999001176.SGD","XLV","LU0757428866.USD","LU0029874061.USD","AADR","LU1093756168.USD","XBI","IE00B2B36J28.USD","APIE","PSCH","IBBQ","LABU","TBXU","LU2362541273.HKD","LU0058720904.USD","BK4137","LU0889565916.HKD","BK4023","IE00B19Z9Z06.USD","LU1069344957.HKD","FBT","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675228783","title":"Belite Bio Seeks Tinlarebant Approval in Singapore, UK and Switzerland","url":"https://stock-news.laohu8.com/highlight/detail?id=2675228783","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675228783?lang=en_us&edition=fundamental","pubTime":"2026-10-15 04:01","pubTimestamp":1792008095,"startTime":"0","endTime":"0","summary":"Belite Bio Seeks Tinlarebant Approval in Singapore, UK and SwitzerlandBelite Bio filed marketing applications for tinlarebant to treat Stargardt disease type 1 in Singapore, the UK and Switzerland thr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261014:nNDL2HD55G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","NDAQ","IE00B3QW5Z07.USD","IE00BQXX3D17.EUR","SG9999014039.USD","BLTE","SG9999014021.USD","IE00BN0W2V16.EUR","SG9999014005.SGD","LU2095319765.USD","SG9999014013.SGD","IE00BN0W2W23.USD","BK4007","BK4588","LU0314104364.USD","IE00BKPKM429.USD","BK4585","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","BK4112","IE00BQXX3C00.GBP","LU2210150020.SGD","IE00BQXX3F31.USD","BCDF","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675830322","title":"Belite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2675830322","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675830322?lang=en_us&edition=fundamental","pubTime":"2026-10-15 04:00","pubTimestamp":1792008000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261014:nTUA1CLHCM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BLTE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675322837","title":"Belite Bio - U.S. Nda for Tinlarebant Accepted with Pdufa Target Action Date February 12, 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2675322837","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675322837?lang=en_us&edition=fundamental","pubTime":"2026-10-15 04:00","pubTimestamp":1792008000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261014:nTUA1CLHCM:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BLTE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675322831","title":"Belite Bio - Submits Marketing Authorization Applications for Tinlarebant in Singapore, UK, and Switzerland","url":"https://stock-news.laohu8.com/highlight/detail?id=2675322831","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675322831?lang=en_us&edition=fundamental","pubTime":"2026-10-15 04:00","pubTimestamp":1792008000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261014:nTUA1CLHCM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BLTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673269087","title":"Belite Bio Chief Medical Officer Hendrik Peter Scholl Reports ADS Disposal Valued at $80,048.70","url":"https://stock-news.laohu8.com/highlight/detail?id=2673269087","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673269087?lang=en_us&edition=fundamental","pubTime":"2026-10-06 07:28","pubTimestamp":1791242901,"startTime":"0","endTime":"0","summary":"Belite Bio Chief Medical Officer Hendrik Peter Scholl reports ADS disposal valued at $80,048.70Belite Bio Chief Medical Officer Hendrik Peter Scholl reported selling 500 American depositary shares on ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nNDL5VxsjL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Belite Bio Chief Medical Officer Hendrik Peter Scholl Reports ADS Disposal Valued at $80,048.70","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLTE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672662763","title":"Belite Bio (BLTE) Draws Fresh Valuation Attention After FDA Priority Review And Euretina Spotlight","url":"https://stock-news.laohu8.com/highlight/detail?id=2672662763","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672662763?lang=en_us&edition=fundamental","pubTime":"2026-10-01 22:19","pubTimestamp":1790864395,"startTime":"0","endTime":"0","summary":"Belite Bio (BLTE) is drawing fresh attention after confirming multiple presentations at the Euretina Innovation Spotlight and main Euretina meeting in Vienna, alongside FDA priority review for its Tinlarebant new drug application.\nRecent excitement around Belite Bio has come alongside firm price momentum, with a 30-day share price return of 9.06% and a 90-day gain of 15.82%, while the 1-year total shareholder return of 131.05% and very large 3-year total shareholder return of about 5x...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-blte/belite-bio/news/belite-bio-blte-draws-fresh-valuation-attention-after-fda-pr","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-blte/belite-bio/news/belite-bio-blte-draws-fresh-valuation-attention-after-fda-pr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","BK4007","LABU","BLTE","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672754772","title":"Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2672754772","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672754772?lang=en_us&edition=fundamental","pubTime":"2026-10-01 20:00","pubTimestamp":1790856000,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Oct.  01, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targetin","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/01/3372849/0/en/belite-bio-announces-oral-presentations-at-two-upcoming-medical-conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BLTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671770265","title":"Belite Bio to Present Phase 3 Dragon Topline Results for Tinlarebant in Adolescent Stargardt Disease at Euretina","url":"https://stock-news.laohu8.com/highlight/detail?id=2671770265","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671770265?lang=en_us&edition=fundamental","pubTime":"2026-09-29 08:00","pubTimestamp":1790640022,"startTime":"0","endTime":"0","summary":"Belite Bio to present Phase 3 DRAGON topline results for tinlarebant in adolescent Stargardt disease at EuretinaBelite Bio scheduled oral presentations at Euretina meetings in Vienna, including Phase ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nNDLDLdYT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4585","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014005.SGD","BLTE","IE00BQXX3C00.GBP","SG9999014039.USD","IE00BQXX3D17.EUR","BK4007","LU0314104364.USD","LU2210149790.SGD","IE00BN0W2V16.EUR","SG9999014013.SGD","BK4588","IE00BQXX3F31.USD","LU2095319765.USD","IE00BN0W2T93.GBP","SG9999014021.USD","NDAQ","BK4112","IE00B3QW5Z07.USD","BCDF","IE00BKPKM429.USD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666755328","title":"Belite Bio CFO Chuang Hao-Yuan Sells USD 8.85 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2666755328","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666755328?lang=en_us&edition=fundamental","pubTime":"2026-09-10 07:39","pubTimestamp":1788997165,"startTime":"0","endTime":"0","summary":"Belite Bio CFO Chuang Hao-Yuan sells USD 8.85 million in common sharesBelite Bio CFO Hao-Yuan Chuang sold 66,362 American depositary shares in transactions dated Sept. 4 and Sept. 8, 2026.Sales prices","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL6xW0C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Belite Bio CFO Chuang Hao-Yuan Sells USD 8.85 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BLTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666130587","title":"Mizuho Raises Price Target on Belite Bio to $234 From $220, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2666130587","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666130587?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:09","pubTimestamp":1788952179,"startTime":"0","endTime":"0","summary":"Belite Bio (BLTE) has an average rating of buy and mean price target of $227.33, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BLTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666300172","title":"U.S. Research Roundup-Argan, Mastec, Oracle","url":"https://stock-news.laohu8.com/highlight/detail?id=2666300172","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666300172?lang=en_us&edition=fundamental","pubTime":"2026-09-09 14:55","pubTimestamp":1788936930,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Argan, Mastec, OracleSept 9 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Argan, Mastec and Oracle","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nL4N4510GB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AEO","AVTR","AMRZ","AKTS","BRZE","CTEC","EVMN","ABM","AGX","DYN","FRNW","PLCE","SMOG","TINY","APD","AMRX","BETR","ARMK","ANIP","ASO","CASY","FLNC","DKS","COLL","DECK","CVS","BLTE","CC","ADBU","ADBE","BBOT","CRI","BRKR","CAI","RTH","ADBG","A","CLH","AIRR","FSLR","ARKG","TXG","STYL","IBAT","CHYM","ANF","FIGR","BBWI","CRK","EXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665379127","title":"Belite Bio Price Target Raised to $245.00/Share from $214.00 by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2665379127","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665379127?lang=en_us&edition=fundamental","pubTime":"2026-09-08 23:30","pubTimestamp":1788881400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BLTE/analyst-ratings","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLTE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665853373","title":"Belite Bio, Inc : H.c. Wainwright Raises Target Price to $245 from $214","url":"https://stock-news.laohu8.com/highlight/detail?id=2665853373","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665853373?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:54","pubTimestamp":1788872092,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nAZN4TIZ3U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BLTE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://investors.belitebio.com;belitebio.com","stockEarnings":[{"period":"1week","weight":0.0356},{"period":"1month","weight":-0.0325},{"period":"3month","weight":-0.0415},{"period":"6month","weight":-0.0056},{"period":"1year","weight":0.3865},{"period":"ytd","weight":-0.0372}],"compareEarnings":[{"period":"1week","weight":-0.0071},{"period":"1month","weight":-0.0104},{"period":"3month","weight":-0.0023},{"period":"6month","weight":0.0396},{"period":"1year","weight":0.1356},{"period":"ytd","weight":0.1245}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.020711},{"month":2,"riseRate":0.75,"avgChangeRate":0.070972},{"month":3,"riseRate":0.25,"avgChangeRate":-0.067883},{"month":4,"riseRate":0.25,"avgChangeRate":-0.011914},{"month":5,"riseRate":0.6,"avgChangeRate":0.032881},{"month":6,"riseRate":0.4,"avgChangeRate":0.163367},{"month":7,"riseRate":1,"avgChangeRate":0.188852},{"month":8,"riseRate":0.2,"avgChangeRate":0.073935},{"month":9,"riseRate":0.6,"avgChangeRate":0.03995},{"month":10,"riseRate":0.6,"avgChangeRate":0.161477},{"month":11,"riseRate":0.6,"avgChangeRate":0.098321},{"month":12,"riseRate":0.5,"avgChangeRate":0.042173}],"exchange":"NASDAQ","name":"Belite Bio, Inc.","nameEN":"Belite Bio, Inc.","securityTypeName":"DR","adrRate":"1:1"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Belite Bio, Inc.(BLTE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Belite Bio, Inc.(BLTE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Belite Bio, Inc.,BLTE,Belite Bio, Inc.股票,Belite Bio, Inc.股票老虎,Belite Bio, Inc.股票老虎国际,Belite Bio, Inc.行情,Belite Bio, Inc.股票行情,Belite Bio, Inc.股价,Belite Bio, Inc.股市,Belite Bio, Inc.股票价格,Belite Bio, Inc.股票交易,Belite Bio, Inc.股票购买,Belite Bio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Belite Bio, Inc.(BLTE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Belite Bio, Inc.(BLTE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}